[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"epilepsy-generalized\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:epilepsy-generalized":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,53,86,112],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100645320","non-invasive-low-intensity-focused-ultrasound-stimulation-for-drug-resistant-epilepsy-100645320",false,"NCT07680842","Non-Invasive Low Intensity Focused Ultrasound Stimulation for Drug-Resistant Epilepsy","Pilot Study of Non-Invasive Low Intensity Focused Ultrasound as an Adjunctive Treatment for Drug-Resistant Epilepsy","Inclusion Criteria\n\n* Male or female between 21 and 65 years of age at screening\n* Clinical diagnosis of drug-resistant epilepsy with on average, 4 or more seizures per month.\n* Able to provide informed consent (or assent when applicable) by the subject or subject's legal representative.\n* Be willing to undergo a brain MRI.\n* Be able and willing to wear a headband during the treatment duration.\n* Be able to complete scheduled visits and daily seizure logs.\n\nExclusion Criteria\n\n* Has a craniotomy or pathologic intracranial lesion (e.g. vascular malformations) in the trajectory of the focused ultrasound beam.\n* Pregnant, breastfeeding, is attempting pregnancy, or unwilling to practice birth control during participation in the study.\n* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.\n* Has any unstable medical or psychiatric disease.\n* Any contraindications for completing a brain MRI scan.\n* Has evidence of any other clinically relevant neurological disorder at the time of screening, including Alzheimer's disease, frontotemporal dementia, Huntington's disease, amyotrophic lateral sclerosis, and multiple sclerosis.","ALL","21 Years","65 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this study is to investigate the effects of a non-invasive, low intensity focused ultrasound (LIFU) stimulation on seizure frequency and the epileptogenic network in drug-resistant epilepsy. LIFU uses focused sound waves to modulate deep brain regions and to enable changes in brain network activity. Encephalography (EEG) and behavioral tasks will also be used to study how LIFU affects brain activity.",[27,28,29,30,31,32,33],"Drug-Resistant Epilepsy","Epilepsy","Epilepsy (Treatment Refractory)","Epilepsy Comorbidities","Epilepsy, Drug Resistant","Epilepsy, Generalized","Epilepsy, Focal",[35,27,28,36,37,38,39],"Seizures","Transcranial Ultrasound Stimulation","Focused ultrasound Stimulation","Electroencephalography (EEG)","Low Intensity Focused ultrasound (LIFU)","RECRUITING","2026-06-25",{"date":43,"type":44},"2026-07-02","ACTUAL",{"date":46,"type":44},"2025-07-09",{"date":48,"type":21},"2027-06-01",{"name":50,"class":51},"University of California, San Francisco","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":16,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":66,"conditions":67,"keywords":74,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":52},"100546822","baker-gordon-syndrome-natural-history-study-100546822","NCT06399952","Baker Gordon Syndrome Natural History Study","A Prospective, Longitudinal and Observational Natural History Study for Children and Adults With Baker Gordon Syndrome - Genetic Autism Alliance","BAGOS","Inclusion Criteria:\n\n* Genetically confirmed diagnosis of Baker Gordon syndrome.\n* 0-99 years\n* Ability to send medical records and diagnostic test results.\n* Ability to complete tests and questionnaires.\n\nExclusion Criteria:\n\n• The presence of another condition or co-morbidity unrelated to Baker Gordon syndrome, that affects neurodevelopment.\n\nIn this study, the primary caregivers\u002FLAR for each participant diagnosed Baker Gordon Syndrome will be also considered participants.\n\nCaregivers\u002FLAR will have to meet the following inclusion criteria:\n\n* \\>18 years.\n* Legal caregiver of the patient diagnosed with a Baker Gordon Syndrome.\n* Willingness to follow study procedures, as assessed by the research team.\n* Willingness to sign the consent form.\n* Ability to understand all the information regarding the study, as assessed by the research team.\n\nCaregivers\u002FLAR Exclusion Criteria:\n\n• Less than 18 years old.","0 Years","99 Years",{"count":64,"type":21},50,"OBSERVATIONAL","The goal of this study is to conduct a prospective, longitudinal assessment of the natural clinical progression of children and adults with Synaptotagmin1-Associated Neurodevelopmental Disorder also known as Baker Gordon Syndrome (BAGOS). This will be performed by acquiring baseline measurements and developing effective outcome measures and diagnostic tools for the disorder, to prepare the healthcare system for future clinical trials.",[68,69,70,71,72,32,73],"Rare Diseases","Autism or Autistic Traits","Development Delay","SYT-SSX Fusion Protein Expression","Sleep Disorder","Motor Delay",[75,59,76],"Baker Gordon Syndrome","Synaptotagmin 1-Associated Neurodevelopmental Disorder","2026-06-01",{"date":79,"type":44},"2026-06-03",{"date":81,"type":44},"2024-04-30",{"date":83,"type":21},"2027-05-05",{"name":85,"class":51},"University of Missouri-Columbia",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":16,"minAge":93,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":22,"phases":97,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":52},"100575236","phase-2-a-study-evaluating-npt-2042-versus-placebo-in-subjects-aged-16-75-years-with-genetic-generalized-epilepsy-gge-and-absence-seizures-100575236","NCT06769659","A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures","A Single-center, Double-blind, Placebo-controlled Crossover Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures","Inclusion Criteria:\n\n1. Subject is capable of and provides consent\u002Fassent, and the study participant's parent\u002Flegal representative\u002Fcaregiver provides signed informed consent for minor study participants, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF)\n2. Subject is aged 16-75 years at the time of consent\u002Fassent\n3. Subject is diagnosed with genetic generalized epilepsy with absence seizures (consistent with the International League Against Epilepsy (ILAE) Classification of Seizures (2017))\n4. Subject has electroencephalogram (EEG) evidence of bilateral synchronous generalized paroxysmal spike-wave (2.5 Hz to 6 Hz) bursts lasting 3 seconds or more at least 4 times on the screening 72-hour ambulatory EEG.\n5. Subject has been on a stable dose of at least one antiseizure medication (ASM) for at least 30 days. Vagal nerve stimulation at stable settings (for at least 30 days before screening), without use of the magnet, is also acceptable.\n6. Subject has normal cognition and no clinically significant abnormalities on neurological examination at screening in the opinion of the Investigator\n7. Subject is in otherwise good health (with the exception of epilepsy), as determined by the investigator, and as documented in the medical history, physical examination, and screening laboratory investigations\n8. Subject has a body mass index (BMI) between 18 and 40 kg\u002Fm2 inclusive, at screening\n9. Female subjects of child-bearing potential and all men agree to use of highly effective methods of contraception during the study and for 28 days after last dose of study drug\n10. Subject (and parent\u002Fcaregiver, if applicable) is able to communicate with the investigator and to understand and comply with all study requirements, including the clinic visit schedule\n\nExclusion Criteria:\n\n1. Subject has metabolic or mitochondrial encephalopathies, seizures associated with structural abnormalities, or infection-related seizures.\n2. Subject has a developmental epileptic encephalopathy (e.g. Lennox-Gastaut syndrome)\n3. Subject has a history of convulsive status epilepticus within the past year.\n4. Subject has a history of surgical intervention for treatment of epilepsy\n5. Subject has a history of nonepileptic seizures (e.g., metabolic, structural, or paroxysmal non epileptic seizures)\n6. Subject has severe intellectual disability, severe autism spectrum disorder, or severe developmental disorder such that the subject cannot consent or assent to participate or cannot cooperate with the study procedures\n7. Female subject who is pregnant or lactating\n8. Subject has any clinically significant laboratory abnormality which, in the opinion of the investigator, will exclude the subject from the study\n9. Subject has an active CNS infection, demyelinating disease, degenerative neurological disease, or any CNS disease deemed to be progressive during the course of the study that may confound the interpretation of the study results\n10. Subject has any clinically significant psychiatric illness, psychological or behavioral problems which, in the opinion of the investigator, would interfere with the subject's ability to participate in the study, including but not limited to the following:\n\n    1. Subject has active suicidal ideation prior to study entry as indicated by a positive response (\"yes\") to either Question 4 or Question 5 of the Columbia Suicide Severity Rating Scale (C-SSRS)\n    2. Study participant has a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt)\n11. Subject is suffering from clinically significant active liver disease, porphyria or has a family history of severe hepatic dysfunction indicated by abnormal liver function tests greater than three times the upper limit of normal (AST and ALT)\n12. Subject has a DSM-V diagnosis of alcohol or drug abuse, or drug addiction within the past 12 months\n13. Subject has participated in any other trials involving an investigational product or device within 30 days of screening or longer, as required by local regulations\n14. Subject is currently using prohibited medications or products\n15. Subject is unable to complete ingestion of four placebo SGCs with a minimum of eight ounces of water at screening\n16. Subject (and parent\u002Fcaregiver, if applicable) has daily commitments during the study duration that would interfere with attending all study visits\n17. Positive urine drug test for substance of abuse or illegal recreational substances at screening","16 Years","75 Years",{"count":96,"type":21},12,[98],"PHASE2","This study will compare the effect of NPT 2042 and placebo in subjects with GGE on the frequency and duration of electroencephalographic absence seizures, separated by a 14-day washout period. The study will be a single-center, double-blind, crossover study with subjects receiving either NPT 2042 BID orally or matching placebo BID in each of two treatment periods. Two doses of NPT 2042 will be evaluated.",[32,101],"Epilepsy, Absence","2026-05-27",{"date":104,"type":44},"2026-05-29",{"date":106,"type":44},"2025-03-11",{"date":108,"type":21},"2026-10-30",{"name":110,"class":111},"NeuroPro Therapeutics, Inc.","INDUSTRY",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":119,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":22,"phases":122,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":135},"100560624","phase-3-ono-2017-study-japanese-patients-with-primary-generalized-tonic-clonic-seizures-100560624","NCT06579573","ONO-2017 Study Japanese Patients With Primary Generalized Tonic Clonic Seizures.","ONO-2017 Phase III Study A Multicenter, Open-label Study in Japanese Patients With Primary Generalized Tonic Clonic Seizures.","Inclusion Criteria:\n\n1. Gender and age: Japanese patients, regardless of gender, aged 12 years or older at the time of informed consent.\n2. Subject has a clinical diagnosis of Primary Generalized Tonic-Clonic (PGTC) seizures in the setting of idiopathic generalized epilepsy.\n3. Subject experiences at least 5 Primary Generalized Tonic-Clonic (PGTC) seizures in 12 weeks.\n4. Subject is currently receiving 1 to a maximum of 3 concomitant Antiepileptic Drugs(AEDs) with fixed dosing regimens\n\nExclusion Criteria:\n\n1. Subject has a history of status epilepticus that required hospitalization within 15 months prior to enrollment.\n2. Subject has seizure clusters where individual seizures cannot be counted orclassified.\n3. History of non-epileptic or psychogenic seizures.\n4. Subject has a concomitant diagnosis of Partial Onset Seizure(POS).\n5. Subject has a history of any serious drug-induced hypersensitivity reaction (including but not limited to Stevens Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms(DRESS), Drug-induced hypersensitivity syndrome(DIHS)) or any drug-related rash requiring hospitalization.","12 Years",{"count":121,"type":21},15,[123],"PHASE3","To investigate the efficacy and safety of ONO-2017 in combination with antiepileptics in Japanese epileptic patients with generalized tonic-clonic seizures.",[32],"2025-06-15",{"date":128,"type":44},"2025-06-17",{"date":130,"type":44},"2022-07-12",{"date":132,"type":21},"2027-01-31",{"name":134,"class":111},"Ono Pharmaceutical Co., Ltd.",25]